Will Soghikian
Stock Analyst at Leerink Partners
(0.76)
# 4,187
Out of 5,126 analysts
7
Total ratings
20%
Success rate
-14.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Will Soghikian
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Hold | $34 | $30.48 | +11.55% | 2 | Oct 27, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $0.6889 | +480.64% | 1 | Oct 12, 2026 | |
| EPA: GNFT Genfit S.A. | Initiated Coverage: Buy | €15.00 | €10.94 | +37.11% | 1 | Oct 12, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Buy | $130 | $38.44 | +238.19% | 1 | Oct 12, 2026 | |
| PTGX Protagonist Therapeutics | Initiated Coverage: Buy | $190 | $134.86 | +40.89% | 1 | Oct 12, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $40 | $9.20 | +334.78% | 1 | Oct 12, 2026 |
Vera Therapeutics
Oct 27, 2026
Reiterated: Hold
Price Target: $34
Current: $30.48
Upside: +11.55%
Connect Biopharma Holdings
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.6889
Upside: +480.64%
Genfit S.A.
Oct 12, 2026
Initiated Coverage: Buy
Price Target: €15.00
Current: €10.94
Upside: +37.11%
Nektar Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $130
Current: $38.44
Upside: +238.19%
Protagonist Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $190
Current: $134.86
Upside: +40.89%
Q32 Bio
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $9.20
Upside: +334.78%